Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency VIC Library | Available |
Table of Contents:; 1. HISTORY OF IMMUNOTHERAPY -- 2. PRINCIPLES OF IMMUNOLOGY AND IMMUNOTHERAPY -- 3. CYTOKINES IN IMMUNOTHERAPY -- 4. IMMUNE CHECKPOINT INHIBITORS -- 5. BACILLUS CALMETTE-GUÉRIN - 6. ORAL IMMUNOMODULATORY AGENTS --7. ACTIVE IMMUNITY: VACCINE THERAPY -- 8. PASSIVE/ADOPTIVE IMMUNOTH…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
Table of Contents:; Transforming nursing through knowledge : the conceptual and programmatic underpinnings of RNAO?s BPG program -- The anatomy of a rigorous best practice guideline development process -- Creating healthy workplaces : enabling clinical excellence -- Forging the way with implementat…
c.1 BC Cancer Agency VAN Library | Available |
Table of contents:; History of Cancer Immunotherapy -- Section I: Basic Principles of Tumor Immunology -- Section II: Cancer Immunotherapy Targets and Classes -- Section III: Immune Function in Cancer Patients -- Section IV: Disease-Specific Treatments and Outcomes -- Section V: Regulatory Aspects …
c.1 BC Cancer Agency VAN Library | Available |
Overview of skin issues related to the oncology patient; Common drug reactions with cutaneous manifestations; Benign skin disorders : impact on cancer therapy; Malignant cutaneous diseases; Wound care products and treatments; Radiation-induced skin reactions; Systemic therapy-induced skin reactions…
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency KEL Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available | ||
c.1 BC Cancer Agency CN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
"Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia…